| Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics |
228 |
| High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma |
68 |
| Targeting Autophagy in Cancer |
59 |
| Analytical Performance of the ThyroSeq v3 Genomic Classifier for Cancer Diagnosis in Thyroid Nodules |
52 |
| Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study |
50 |
| Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature |
43 |
| Targeting autophagy using natural compounds for cancer prevention and therapy |
43 |
| Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics |
40 |
| Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial |
35 |
| The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia |
35 |
| Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities |
33 |
| The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy |
32 |
| Clinical and molecular characterization of early-onset colorectal cancer |
31 |
| The Impact of the Rising Colorectal Cancer Incidence in Young Adults on the Optimal Age to Start Screening: Microsimulation Analysis I to Inform the American Cancer Society Colorectal Cancer Screening Guideline |
30 |
| Individual Meaning-Centered Psychotherapy for the Treatment of Psychological and Existential Distress: A Randomized Controlled Trial in Patients With Advanced Cancer |
29 |
| Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 983 Cases |
28 |
| The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening |
27 |
| Phase 1 Trial Evaluating Cisplatin, Gemcitabine, and Veliparib in 2 Patient Cohorts: Germline BRCA Mutation Carriers and Wild-Type BRCA Pancreatic Ductal Adenocarcinoma |
27 |
| Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies |
26 |
| Bone Marrow Versus Mobilized Peripheral Blood Stem Cells in Haploidentical Transplants Using Posttransplantation Cyclophosphamide |
26 |
| Suicide risk among cancer survivors: Head and neck versus other cancers |
26 |
| The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas |
25 |
| Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma |
25 |
| Leptomeningeal metastasis from systemic cancer: Review and update on management |
25 |
| A Phase 2 Trial of Regorafenib as a Single Agent in Patients With Chemotherapy-Refractory, Advanced, and Metastatic Biliary Tract Adenocarcinoma |
25 |
| Checkpoint Inhibitors in Triple-Negative Breast Cancer (TNBC): Where to Go From Here |
23 |
| Targeting HER2 in Colorectal Cancer: The Landscape of Amplification and Short Variant Mutations in ERBB2 and ERBB3 |
23 |
| The impact of psychosocial stress and stress management on immune responses in patients with cancer |
22 |
| Promoting Resilience in Adolescents and Young Adults With Cancer: Results From the PRISM Randomized Controlled Trial |
22 |
| Does socioeconomic status account for racial and ethnic disparities in childhood cancer survival? |
22 |
| Beyond Symptomatic Relief for Chemotherapy-Induced Peripheral Neuropathy: Targeting the Source |
21 |
| Increasing Prevalence of Human Papillomavirus-Positive Oropharyngeal Cancers Among Older Adults |
21 |
| Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer |
21 |
| Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series |
21 |
| Promising efficacy of SHR- a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China |
20 |
| Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone |
20 |
| Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma |
20 |
| Quantitative imaging of cancer in the postgenomic era: Radio(geno)mics, deep learning, and habitats |
20 |
| Safety Profile of Avelumab in Patients With Advanced Solid Tumors: A Pooled Analysis of Data From the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel 200 Clinical Trials |
19 |
| Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer |
19 |
| Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors: Practical Recommendations for Diagnosis and Clinical Management |
19 |
| Medical financial hardship among cancer survivors in the United States |
19 |
| Quantitative Survival Impact of Composite Treatment Delays in Head and Neck Cancer |
19 |
| Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients |
19 |
| Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial |
19 |
| Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group |
18 |
| CSF3R Mutations Are Frequently Associated With Abnormalities of RUNX CBFB, CEBPA, and NPM1 Genes in Acute Myeloid Leukemia |
18 |
| Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study |
18 |
| Margins in Breast Cancer: How Much Is Enough? |
18 |
| Unmet Need for Clinician Engagement Regarding Financial Toxicity After Diagnosis of Breast Cancer |
18 |
